D2M Biotherapeutics United States

A human-genetics driven next generation immunity-oncology company
Nan Bing
CEO 
Functionality

Dao Tun GmbH Switzerland

Dao Tun is a consulting company, founded in 2019, specialised in cross-border collaboration between Europe and China, primarily in the healthcare and life science industry.
Dao Tun is based in the Basel region, one of the world's leading clusters for Pharma and Life Sciences and also part of the trinational Biovalley region (Switzerland, Germany, France).
Dao Tun team provides customised strategy and execution plan via in-depth interview and targeted research; quickly gains insights into the association and matching between potential partners to make accurate and effective connections; simplifies the processes, reduces the cost of communication, and establishes the trust with full care.
Dao Tun is a bridge builder who excels at understanding and interpreting their interests and needs, and aligning perspectives of different stakeholders and across cultures for win-win-win situation.

Dr. Tianke Wang
Dr. Tianke Wang
CEO 
Functionality

Dawn Biopharmaceuticals Inc. United States

Dawn Biopharmaceuticals Inc (DBI) is a US firm founded by Gordon Lee, MD (UK MBChB), MBA (Wharton) who has access to a proprietary cell-based immunotherapeutic product for clinical development in the US. The product is a multivalent cancer therapy that integrates multiple anti-cancer mechanisms in one modifiable platform. The product is tumor-homing, disables the local tumor defenses and expresses a therapeutic cytokine in the cancer - but not systemically.

(Please note that the website is pending.)
Website:
dawnbio.net
Company Size (Fulltime employees)
Year of foundation
2020
Headquartner in China
Assets Information 1
Initial round
Gordon Lee
Founder 
Functionality

Debn

Prostate biopsy needle with antibiotic coating .
Website:
Denbn.eu
Company Size (Fulltime employees)
Year of foundation
2017
Partnering Objectives
Please specify your partnering goal
Funding
Headquartner in China
Medtech Information 1
Drug eluting biopsy needle|biopsy needle realase active layer during biopsy procedure preventing from infections following biopsy procedure|Usa.europe
Medtech Development Stage
Mr. Michal Kruzycki
Ceo 
Functionality

Device of tomorrow capital llc United States

US dollar fund,focusing on medical device and Medtech area.
Partnering Objectives
Headquartner in China
Yan Henry
Managing partner 

DHVC United States

Life Science and Healthcare Venture Capital Investor
Website:
www.dh.vc
Company Size (Fulltime employees)
Year of foundation
2013
Partnering Objectives
Please specify your partnering goal
Investment
Headquartner in China
Medtech Development Stage
Ali Farahanchi
Managing Director 
Functionality

Drive Therapeutics, LLC United States

Drive Therapeutics is developing a novel, long acting, bispecific nucleic acid therapeutic to block the angiogenesis, inflammation, and fibrosis underlying retinal disease. Drive’s lead program is a bispecific aptamer therapeutic made up of two well validated components: a pan-specific anti-VEGF-A aptamer and an anti-Interleukin-8 (IL8) aptamer. Drive’s lead program will mitigate poor patient response to existing anti-VEGF therapy, improve outcomes and reduce patient burden. By targeting both angiogenesis and a critical immune pathway that drives both inflammation and angiogenesis, Drive’s bispecific inhibitor is the key to overcoming the limitations of VEGF monotherapy. In addition to current candidates, Drive’s aptamer therapeutic discovery platform will allow for streamlined, efficient development of new therapies to pathologically relevant ophthalmologic targets.
Company Size (Fulltime employees)
Year of foundation
2019
Partnering Objectives
Headquartner in China
Ryan Quick
Co-founder and COO 
Functionality

Dyadic International, Inc. United States

Dyadic International, Inc. is a global biotechnology company focused on improving and applying its proprietary C1 gene expression platform, based on a patented and proprietary genetically modified strain of the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), to address opportunities in the human and animal health markets. C1 is a potentially game-changing biopharmaceutical gene expression platform that may help bring biologic vaccines, drugs and other biologic products to market faster and more efficiently than existing expression platforms, such as Chinese hamster ovary (CHO) cells, E. coli, yeast and baculovirus in greater volumes, at lower cost and with new properties that can improve access and cost to patients and the healthcare system.

Company Size (Fulltime employees)
Year of foundation
1979
Headquartner in China
Biotech/Pharma Asset Stage
Slides Deck
(pdf, 1.58MB)
Ping Rawson
Ping Rawson
CFO 
Functionality

Eisai China

Japanese top 5 Pharma company
Website:
Eisai.com.cn
Partnering Objectives
Headquartner in China
colin Lin
BD AD 

Elasmogen Ltd United Kingdom

Elasmogen, a next generation biologics company, develops soloMERs which are high affinity binding, single-domains; they are small (9% of an antibody), highly stable proteins and crucially are outside the complex/competitive antibody patent landscape. soloMERs are pre-disposed to generating potent neutralisers by binding to novel or cryptic epitopes. Their small size makes them ideal for both site-specific delivery and penetration of solid tumours. Our lead product, ADCP165, is an anti-ROR1 soloMER drug conjugate being co-developed with Almac Discovery. This program is tracking for entry into the clinic 2022/3 with follow on products in the pipeline. In addition our lead anti-auto-immune inflammatory domain, ELN/22, a tetravalent, bi-paratopic anti-TNF product is being developed for oral delivery for the treatment of IBD.
We are currently looking for partners for our existing assets and also companies who would like to access our powerful, patent protected soloMER platform to develop new products.
Company Size (Fulltime employees)
Year of foundation
2016
Please specify your partnering goal
Licensing of existing assets and co-development of new therapeutic development
Headquartner in China
Dr. Caroline Barelle
CEO